[MSI-high ascending colon cancer treated with second-line ipilimumab plus nivolumab for conversion surgery:a case report].
Nihon Shokakibyo Gakkai Zasshi
; 120(3): 256-262, 2023.
Article
in Ja
| MEDLINE
| ID: mdl-36908144
ABSTRACT
A 68-year-old woman with ascending colon cancer was the patient (cT4bN2M1a [LYM] cStage IVA, BRAF V600E mutation-positive, and MSI-high). She was given modified FOLFOXIRI as first-line therapy but did not respond. The infiltration of the primary lesion in the abdominal wall was alleviated, allowing conversion surgery to be performed.
Full text:
1
Database:
MEDLINE
Main subject:
Colonic Neoplasms
/
Nivolumab
Limits:
Aged
/
Female
/
Humans
Language:
Ja
Journal:
Nihon Shokakibyo Gakkai Zasshi
Year:
2023
Type:
Article